Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advanceClinical trial sites activated for GB-4362 (MMAE neutralizer);...
Read moreDetails